Online inquiry

IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8458MR)

This product GTTS-WQ8458MR is a type of mRNA modified with 5-Methyl-CTP & Pseudo-UTP, which ecodes the monoclonal antibody that targets TLR3 Agonist. The antibody can be applied in Cervical dysplasia vaccine research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Mycobacterium tuberculosis variant bovis; Alphapapillomavirus 9
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8458MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12000MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MM-121
GTTS-WQ13626MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA R4930
GTTS-WQ411MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ10879MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ4265MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB-033
GTTS-WQ13196MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-04950615
GTTS-WQ8363MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ14977MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SHR-1314
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW